GlassScriptPhysician profile
Ahmad Zarzour
NPI 1992149041
$23,802.44
in general payments reported to CMS, 2019-2025
39 companies · $405 in 2025
The $405 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2021: $2,430 · 2022: $3,852 · 2023: $1,746 · 2024: $15K · 2025: $405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Food and Beverage: $2,109 · Honoraria: $1,200 · Education: $89.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,840.00 |
| Food and Beverage | $2,109.40 |
| Honoraria | $1,200.00 |
| Education | $89.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $12,837.32 | 2022-2025 | Enhertu, Injectafer, Vanflyta |
| Pharmacosmos Therapeutics INC. | $4,222.55 | 2021-2022 | |
| Sirtex Medical INC | $2,694.93 | 2024 | Sir-Spheres Microspheres |
| Pfizer INC. | $1,256.49 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $378.08 | 2019-2025 | Lynparza, Tagrisso, Imfinzi |
| Genentech USA, INC. | $284.50 | 2019-2025 | Polivy, Phesgo, Lunsumio |
| Tempus Ai, INC | $246.26 | 2024 | Xt Cdx |
| Eisai INC. | $190.35 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $146.65 | 2022-2025 | Reblozyl, Opdualag |
| Merck Sharp & Dohme LLC | $138.06 | 2022-2024 | Keytruda, Welireg, Lynparza |
| Celgene Corporation | $135.92 | 2022-2024 | Reblozyl, Pomalyst |
| Bayer Healthcare Pharmaceuticals INC. | $134.49 | 2019-2025 | |
| Pinnacle Biologics, INC | $124.56 | 2024 | Photofrin |
| Takeda Pharmaceuticals U.S.A., INC. | $115.74 | 2022-2024 | Alunbrig, Iclusig |
| Janssen Biotech, INC. | $103.55 | 2021-2025 | Rybrevant, Erleada, Talvey |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $92.63 | 2023-2025 | Jakafi, Monjuvi, Pemazyre |
| Seagen INC. | $78.95 | 2021-2023 | Padcev |
| Astellas Pharma US INC | $72.20 | 2023-2025 | Xtandi, Padcev |
| Gilead Sciences, INC. | $59.28 | 2023-2025 | Trodelvy |
| Karyopharm Therapeutics INC. | $49.79 | 2024 | Xpovio |
| Novartis Pharmaceuticals Corporation | $38.81 | 2022-2025 | |
| Lilly USA, LLC | $33.43 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| G1 Therapeutics, INC. | $32.88 | 2022-2023 | Cosela |
| Kite Pharma, INC. | $32.18 | 2022-2024 | Yescarta |
| Amgen INC. | $31.89 | 2022-2023 | Lumakras |
| Genzyme Corporation | $25.72 | 2024 | |
| Dendreon Pharmaceuticals LLC | $24.45 | 2023 | Provenge |
| Array Biopharma INC | $23.36 | 2025 | Lorbrena, Xalkori, Braftovi |
| Taiho Oncology, INC. | $22.70 | 2025 | |
| Adaptive Biotechnologies Corporation | $21.43 | 2023 | Clonoseq |
| Agios Pharmaceuticals, INC. | $20.11 | 2025 | Pyrukynd |
| Mirati Therapeutics, INC. | $19.21 | 2023 | Krazati |
| Deciphera Pharmaceuticals INC. | $17.61 | 2025 | Qinlock, Romvimza |
| Sumitomo Pharma America, INC. | $17.61 | 2025 | Orgovyx |
| Apellis Pharmaceuticals, INC. | $17.18 | 2022 | |
| Genmab U.S., INC. | $16.98 | 2025 | Epkinly |
| Sobi, INC | $14.94 | 2025 | |
| Springworks Therapeutics, INC. | $14.93 | 2024 | Ogsiveo |
| Kyowa Kirin, INC. | $14.72 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmad Zarzour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.